Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.
Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.
With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.
Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.
Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.
Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) for patients with EGFR Exon20 insertion-positive metastatic non-small cell lung cancer (mNSCLC). Results showed a median overall survival of 24 months with a 28% objective response rate after over a year of follow-up. Mobocertinib is under priority review by the U.S. FDA and could become the first oral therapy targeting EGFR Exon20 mutations, with a manageable safety profile.
Takeda Pharmaceutical Company Limited (NYSE: TAK) reported financial results for FY2020, ending March 31, 2021, revealing a total revenue of JPY 3,197.8 billion, a decline of 2.8% year-on-year, but an underlying growth of 2.2%. The operating profit surged by 407.2% to JPY 509.3 billion, driven by non-core asset sales. The company aims for mid-single-digit revenue growth, targeting JPY 5 trillion by FY2030, while anticipating FY2021 as a critical year with increased R&D investments and potential for four regulatory approvals. Net profit rose by 749.9% to JPY 376 billion.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has received recognition from the International Society for Pharmaceutical Engineering (ISPE) with two awards for the 2021 Facility of the Year Awards. The new solid pharmaceutical packaging building in Hikari, Japan, won in the ‘Process Intelligence and Innovation’ category, while the Grange Castle facility in Ireland was honored for ‘Facility Integration’. These accolades highlight Takeda's commitment to advanced manufacturing and digital technologies, ensuring high-quality production and efficient supply chains for its oncology treatments.
Takeda Pharmaceutical Company announced that the FDA has granted priority review for its New Drug Application (NDA) for mobocertinib (TAK-788). This oral therapy targets EGFR Exon20 insertion mutations in metastatic non-small cell lung cancer (mNSCLC) patients who have previously undergone platinum-based chemotherapy. Mobocertinib has already received Orphan Drug Designation and Breakthrough Therapy Designation from the FDA. The NDA is based on a Phase 1/2 trial involving 114 patients and is part of the FDA's accelerated approval program, facilitated by Project Orbis.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced a conference call on April 6, 2021, to discuss updates on its Wave 1 pipeline portfolio, which includes several New Molecular Entities (NMEs) with regulatory filings expected by year-end FY2021. The agenda features key presentations on innovative treatments, including Maribavir (TAK-620) for post-transplant CMV infection and Soticlestat (TAK-935) for Dravet Syndrome. Takeda emphasizes its focus on organic and sustainable revenue growth over the coming years.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has finalized the sale of a portfolio of around 130 OTC and prescription products to Orifarm Group for up to $670 million USD. This portfolio, which generated FY2020 net sales of approximately $240 million USD, includes key products from various therapeutic areas mainly sold in Europe. Proceeds will be used to reduce debt, aiming for a 2x net debt/adjusted EBITDA target by 2023. The transaction has also involved transitioning approximately 600 employees to Orifarm.
Takeda Pharmaceutical Company has completed the sale of its Consumer Healthcare division to Blackstone for JPY 242 billion. The divestiture includes numerous OTC products generating over JPY 60 billion in revenue. Following the sale, TCHC will operate as Alinamin Pharmaceuticals. Takeda aims to use the proceeds to reduce debt and achieve a net debt/EBITDA ratio of 2x by FY2023. With this transaction, Takeda has surpassed its $10 billion divestiture target, totaling $12.9 billion since January 2019. A pre-tax gain of JPY 140 billion will boost reported net profit for FY2020.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced that the European Medicines Agency (EMA) accepted its regulatory filings for the dengue vaccine candidate, TAK-003. This vaccine is aimed at preventing dengue in individuals aged four to 60. Takeda plans to submit filings in multiple countries including Argentina, Brazil, and Mexico in 2021. The company is also participating in EMA’s parallel assessment assessment process. The pivotal Phase 3 trial demonstrated safety and efficacy over 36 months, highlighting the urgent need for dengue vaccination globally.
Takeda Pharmaceutical presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation the results from the Phase 3 SOLSTICE trial of TAK-620 (maribavir). The study demonstrated a significant increase in CMV viremia clearance among transplant recipients with resistant infections, achieving 62.8% with maribavir against 20.3% with conventional therapies. Maribavir also exhibited lower rates of treatment-related toxicities compared to traditional antiviral options, highlighting its potential as a transformative treatment for CMV infections in transplant patients.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has partnered with IDT Biologika to temporarily use its manufacturing capacity for the COVID-19 vaccine developed by Janssen Pharmaceuticals. This arrangement allows Takeda to support global vaccination efforts while ensuring that its dengue vaccine candidate, TAK-003, can resume production shortly after. The company remains dedicated to addressing both COVID-19 and dengue, acknowledging the significant public health needs associated with these diseases.
FAQ
What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What are Takeda Pharmaceutical's core therapeutic areas?
Where is Takeda Pharmaceutical headquartered?
What recent collaborations has Takeda Pharmaceutical entered into?
How diversified is Takeda's revenue geographically?
What was Takeda's revenue in fiscal 2023?
Who can benefit from Takeda's new drug NBI-1065845?
What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?
How long has Takeda been in the pharmaceutical industry?
In how many countries does Takeda operate?
How does Takeda contribute to the field of major depressive disorder treatment?
